Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis

Hiranmoy Das, Nasreen Abdulhameed, Matthew Joseph, Ramasamy Sakthivel, Hai Quan Mao, Vincent J Pompili

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The stem cell therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber-based ex vivo stem cell expansion technology and proangiogenic growth factors overexpression of human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The progenitor cells were expanded ∼225-fold on nanofiber-based serum-free ex vivo expansion culture technique without inducing differentiation. The expanded cells express high levels of stem cell homing receptor, CXCR4, and adhesion molecule, LFA-1. The nanofiber-expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. These expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and this effect was further augmented by VEGF164 and PDGF-BB, growth factor overexpression. The data indicate that nanofiber-based ex vivo expansion technology can provide an essential number of therapeutic stem cells. Additionally, proangiogenic growth factors overexpression in progenitor cells can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.

Original languageEnglish (US)
Pages (from-to)305-318
Number of pages14
JournalCell Transplantation
Volume18
Issue number3
DOIs
StatePublished - Jun 23 2009

Fingerprint

Nanofibers
Medical Genetics
Stem cells
Fetal Blood
Blood
Stem Cells
Intercellular Signaling Peptides and Proteins
Cell- and Tissue-Based Therapy
Restoration
CXCR4 Receptors
Muscle
Technology
Assays
Culture Techniques
Lymphocyte Function-Associated Antigen-1
Adhesion
Inbred NOD Mouse
SCID Mice
Cells
Availability

Keywords

  • Hematopoietic progenitor stem cells
  • Human umbilical cord blood
  • Limb ischemia
  • Nanofibers
  • Proangiogenic growth factors

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. / Das, Hiranmoy; Abdulhameed, Nasreen; Joseph, Matthew; Sakthivel, Ramasamy; Mao, Hai Quan; Pompili, Vincent J.

In: Cell Transplantation, Vol. 18, No. 3, 23.06.2009, p. 305-318.

Research output: Contribution to journalArticle

Das, Hiranmoy ; Abdulhameed, Nasreen ; Joseph, Matthew ; Sakthivel, Ramasamy ; Mao, Hai Quan ; Pompili, Vincent J. / Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. In: Cell Transplantation. 2009 ; Vol. 18, No. 3. pp. 305-318.
@article{b226929566b44219a9bcab05053124b7,
title = "Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis",
abstract = "The stem cell therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber-based ex vivo stem cell expansion technology and proangiogenic growth factors overexpression of human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The progenitor cells were expanded ∼225-fold on nanofiber-based serum-free ex vivo expansion culture technique without inducing differentiation. The expanded cells express high levels of stem cell homing receptor, CXCR4, and adhesion molecule, LFA-1. The nanofiber-expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. These expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and this effect was further augmented by VEGF164 and PDGF-BB, growth factor overexpression. The data indicate that nanofiber-based ex vivo expansion technology can provide an essential number of therapeutic stem cells. Additionally, proangiogenic growth factors overexpression in progenitor cells can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.",
keywords = "Hematopoietic progenitor stem cells, Human umbilical cord blood, Limb ischemia, Nanofibers, Proangiogenic growth factors",
author = "Hiranmoy Das and Nasreen Abdulhameed and Matthew Joseph and Ramasamy Sakthivel and Mao, {Hai Quan} and Pompili, {Vincent J}",
year = "2009",
month = "6",
day = "23",
doi = "10.3727/096368909788534870",
language = "English (US)",
volume = "18",
pages = "305--318",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "3",

}

TY - JOUR

T1 - Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis

AU - Das, Hiranmoy

AU - Abdulhameed, Nasreen

AU - Joseph, Matthew

AU - Sakthivel, Ramasamy

AU - Mao, Hai Quan

AU - Pompili, Vincent J

PY - 2009/6/23

Y1 - 2009/6/23

N2 - The stem cell therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber-based ex vivo stem cell expansion technology and proangiogenic growth factors overexpression of human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The progenitor cells were expanded ∼225-fold on nanofiber-based serum-free ex vivo expansion culture technique without inducing differentiation. The expanded cells express high levels of stem cell homing receptor, CXCR4, and adhesion molecule, LFA-1. The nanofiber-expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. These expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and this effect was further augmented by VEGF164 and PDGF-BB, growth factor overexpression. The data indicate that nanofiber-based ex vivo expansion technology can provide an essential number of therapeutic stem cells. Additionally, proangiogenic growth factors overexpression in progenitor cells can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.

AB - The stem cell therapy for treating ischemic diseases is promising; however, the limited availability and compromised quality of progenitor cells in aged and diseased patients limit its therapeutic use. Here we report a nanofiber-based ex vivo stem cell expansion technology and proangiogenic growth factors overexpression of human umbilical cord blood (UCB)-derived progenitor cells to enhance angiogenic potential of therapeutic stem cells. The progenitor cells were expanded ∼225-fold on nanofiber-based serum-free ex vivo expansion culture technique without inducing differentiation. The expanded cells express high levels of stem cell homing receptor, CXCR4, and adhesion molecule, LFA-1. The nanofiber-expanded stem cells uptake AcLDL effectively, and migrate efficiently in an in vitro transmigration assay. These expanded cells can also differentiate into endothelial and smooth muscle cells in vitro. In a NOD/SCID mouse hind limb vascular injury model, nanofiber-expanded cells were more effective in blood flow restoration and this effect was further augmented by VEGF164 and PDGF-BB, growth factor overexpression. The data indicate that nanofiber-based ex vivo expansion technology can provide an essential number of therapeutic stem cells. Additionally, proangiogenic growth factors overexpression in progenitor cells can potentially improve autologous or allogeneic stem cell therapy for ischemic diseases.

KW - Hematopoietic progenitor stem cells

KW - Human umbilical cord blood

KW - Limb ischemia

KW - Nanofibers

KW - Proangiogenic growth factors

UR - http://www.scopus.com/inward/record.url?scp=67449087553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449087553&partnerID=8YFLogxK

U2 - 10.3727/096368909788534870

DO - 10.3727/096368909788534870

M3 - Article

VL - 18

SP - 305

EP - 318

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 3

ER -